SCHEMBL1626903

SCHEMBL1626903

CC(=O)C(N)C(=O)Nc1cccc(Nc2ncc(C(F)(F)F)c(NCc3ncccc3N(C)S(C)(=O)=O)n2)c1

nearest known ligand 0.82

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
▸ PTK2 Q05397 20/20 0.82

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1627489 0.91 PTK2 (1.00) PTK2
SCHEMBL1626904 0.87 PTK2 (0.78) PTK2
SCHEMBL12721480 0.86 PTK2 (1.00) PTK2
SCHEMBL29853264 0.85 PTK2 (1.00) PTK2
SCHEMBL1627666 0.85 PTK2 (1.00) PTK2
SCHEMBL15633499 0.84 PTK2 (0.87) PTK2
SCHEMBL1627126 0.83 PTK2 (1.00) PTK2
SCHEMBL29853513 0.83 PTK2 (1.00) PTK2
SCHEMBL14478571 0.82 PTK2 (0.77) PTK2
SCHEMBL1625739 0.81 PTK2 (1.00) PTK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240109862-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER INC. 2024-04-04 — — US disclosed
US-10450297-B2 Sulfonyl amide derivatives for the treatment of abnormal cell growth PFIZER, INC. (US) 2019-10-22 — — US disclosed
US-20190047979-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER (US) 2019-02-14 — — US disclosed
US-20170327485-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER (US) 2017-11-16 — — US disclosed
EP-2146779-B1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER PROD INC (US) 2016-08-10 — — EP disclosed
US-20160130250-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER (US) 2016-05-12 — — US disclosed
US-20150080368-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH VERASTEM, INC. (US) 2015-03-19 — — US disclosed
US-20140100368-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH LUZZIO MICHAEL JOSEPH (US) 2014-04-10 — — US disclosed
US-8440822-B2 Sulfonyl amide derivatives for the treatment of abnormal cell growth PFIZER, INC. 2013-05-14 — — US disclosed
US-20130005964-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER, INC. 2013-01-03 — — US disclosed
US-8247411-B2 Sulfonyl amide derivatives for the treatment of abnormal cell growth PFIZER INC (US) 2012-08-21 — — US disclosed
US-20110166120-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER INC. 2011-07-07 — — US disclosed
US-7928109-B2 focal adhesion kinase inhibitor, i.e. FAK inhibitor; tyrosine kinase inhibitors; cancer, osteoporosis; e.g. N-methyl-4-({4-[({3-[methyl(methylsulfonyl)amino]pyrazin-2-yl}methyl)amino]-5-(trifluoromethyl)pyrimidin-2-yl}amino)benzamide hydrochloride PFIZER INC (US) 2011-04-19 — — US disclosed
US-20090054395-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER INC. 2009-02-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140100368-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH GPR119, INSR, LYAR PTK2 4052/4885
US-10450297-B2 Sulfonyl amide derivatives for the treatment of abnormal cell growth GPR119, INSR, LYAR PTK2 4052/4885
US-20150080368-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH GPR119, INSR, LYAR PTK2 4052/4885
US-20110166120-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH GPR119, INSR, LYAR PTK2 4052/4885
US-20170327485-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH GPR119, INSR, LYAR PTK2 4052/4885
US-20190047979-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH GPR119, INSR, LYAR PTK2 4052/4885
US-20130005964-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH GPR119, INSR, LYAR PTK2 4052/4885
US-20240109862-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH GPR119, INSR, LYAR PTK2 4052/4885
US-20090054395-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH GPR119, INSR, LYAR PTK2 4052/4885
US-20160130250-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH GPR119, INSR, LYAR PTK2 4052/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback